Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC (EABM)

Inclusion Criteria:

1. at the age of 18 -70 years old, male or female
2. the non-small cell lung cancer diagnosed by histopathology
3. detected by ARMS to confirm that the EGFR sensitive mutant patients
4. the existence of MRI diagnosis of intracranial metastatic head enhancement, and the presence of imaging evaluating lesions (according to RECIST1.1)
5. have not received prior treatment of intracranial metastases, including radiotherapy, gamma knife, chemotherapy drugs
6. no brain metastasis symptoms, including, increased intracranial pressure, no vomiting, ignoring the papillary edema, no headache, without hemiplegia, ignore things not clear, without epilepsy
7. PS:0 or 1
8. the expected survival time 3 months >
9. patients signed informed consent voluntarily

Exclusion Criteria:

1. 4 weeks before entering the group received operation or operation, the wound has not healed completely
2. into group 2 weeks before receiving immune therapy or treatment of traditional Chinese Medicine
3. serious cardiovascular diseases, including Department of internal medicine, uncontrolled hypertension, unstable angina, myocardial infarction history exists within the past June, severe arrhythmia or pericardial effusion
4. serious infection, need intravenous antibiotic, antifungal or antiviral treatment
5. before entering the group 4 weeks participated in any study drug clinical trial
6. there are serious tumor invasion, oppression by the main bronchus or bronchial stenosis or obstruction, superior vena cava syndrome
7. the existence of herniation of brain tumor apoplexy, epilepsy, and frequent
8. suffering from a mental illness, poor compliance
9. the researchers think that do not fit into the group of cases